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Most clinical studies use conventional methods for survival
analysis and calculate the risk of the event of interest;
however, it is important to understand that the study
population is also at risk of competing events, e.g. death from
other causes. Moreover, the risk of competing events may be
dependent on the participants’ characteristics. Whether
competing risks are taken into account or not, is of major
importance when interpreting study results.
Here, we use a practical example to elucidate the
interpretational differences of absolute risk estimates obtained
with both conventional methods for survival analysis and
competing-risk analysis.
The main difference between conventional methods for
survival analysis and competing-risk analysis is the possibility
to calculate the risk of more than one event when using the
latter method. With competing-risk analysis researchers can
calculate the risk of the main event, and the risk of one or
several competing events. These competing events are deﬁned
by an event that either hinders or fundamentally alters the
probability of having the main event [1]. For example, when
studying a speciﬁc cause of death as the main event, death
due to any other cause is a competing event, or when
studying a speciﬁc primary treatment to a disease, any other
primary treatment is a competing event.
An underlying assumption in conventional survival analysis is
that censoring is non-informative, i.e. each study participant
has the same probability of getting censored independent of
their covariates. If the study participants’ probability of
getting censored depends on their covariates, the underlying
assumption is violated (informative censoring). This could for
instance happen when the studied risk factor is associated
with death (smoking, obesity, metabolic syndrome, etc.) or
associated with any other competing event based on the study
settings. To avoid violation of this assumption, an alternative
is to include several events in the study by use of competing-
risk analysis, and for example use overall death as a
competing event to the main event of the study.
Example: Hypertension and Risk of Prostate Cancer
Here, we use data from the Metabolic Syndrome and Cancer
project (Me-Can) [2], a prospective European cohort study of
almost 290 000 men to illustrate the distinction between the
study ﬁndings from conventional survival and competing-risk
analyses. In Me-Can, we have previously studied metabolic
factors and risk of prostate cancer using both methods [3,4].
This example focuses on the association between
hypertension (systolic blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mmHg) and risk of prostate cancer. All
men were followed from a baseline health examination (date
of blood pressure assessment) until date of prostate cancer
diagnosis, death, migration or end of follow-up, whichever
occurred ﬁrst. In this example we analysed data from 287 675
men, of whom 38% had hypertension at baseline health
examination. Data of follow-up and results of performed
regression analyses can be found in Table 1.
The absolute risk based on conventional survival methods
using the Kaplan–Meier failure estimates is shown in
Figure 1A. It shows that the risk of prostate cancer was
similar for those with and without hypertension. Using
competing-risk methods, we calculated the absolute risk of
prostate cancer with the cumulative incidence function [5], as
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shown in Figure 1B. Here, death was considered as a
competing event to prostate cancer and we found that men
with hypertension had a lower risk of prostate cancer
compared with those without hypertension.
Despite providing different results, both estimates can be
considered to be correct. Each ﬁgure aims to answer a
different research question, which therefore often leads to
misinterpretation. The risk as shown in Figure 1A can be
interpreted as the risk of prostate cancer in a hypothetical
scenario – men can only get prostate cancer and all other
events, including death, are censored. The risk in Figure 1B
can be interpreted as the real-world risk, whereby men can
get prostate cancer or die of any other cause. Other events
(migration and end of follow up) are censored and assumed
to happen at random regardless of hypertension status (or
other covariates) at baseline.
There are two main reasons why our study ﬁndings differ
when using these two methods. Firstly, prostate cancer is a
disease of the elderly (mean age at diagnosis is about 70–
72 years), and many men may have already died from other
causes before they reach the age at which prostate cancer may
be diagnosed. In a conventional survival analysis, this may
result in an overestimation of the risk using Kaplan–Meier
estimates [6]. In our example, this is reﬂected by the observed
higher risk estimates of prostate cancer for both men with
and without hypertension when using conventional methods
(Fig. 1A), compared with competing-risk analysis (Fig. 1B).
Secondly, there is an issue of informative censoring;
hypertension is known to increase risk of death from all
causes. More men with hypertension die and leave the study
cohort, in comparison to men without hypertension. This
could be a reason why there is no difference in the risk of
prostate cancer between men with and without hypertension
when using conventional analysis (Fig. 1A), compared with
the competing-risk analysis (Fig. 1B).
Despite correctly answering two different research questions,
it is important to note that neither analysis gives any insight





Study subjects, n (%) 178 169 (62) 109 506 (38)
Number of prostate
cancer cases, n (%)
3292 (2) 3615 (3)
Incidence rate of prostate cancer* 161.6 258.1
Number of deaths, n (%) 12 068 (7) 17 243 (16)
Incidence rate of death* 592.4 1231.1
Cox regression hazard ratio† 1.00 (Ref.) 0.99 (0.94–1.04)
Fine and Gray regression
sub-distribution
hazard ratio (95% CI)‡
1.00 (Ref.) 0.91 (0.87–0.96)
*Calculated per 100 000 men using conventional survival analysis censoring for all
other events; †Adjusted for smoking (never, former, current), age at health
examination (continuous) and stratiﬁed within the model for sub-cohort and date of
birth (ﬁve categories); ‡Adjusted for smoking (never, former, current), age at health
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Fig. 1 Absolute risk of prostate cancer among men with and without hypertension calculated by conventional survival analysis (A) and competing-risk
analysis (B). The risk calculated by conventional methods reﬂects a hypothetical scenario in which men can only get prostate cancer and all other
events are censored. The risk calculated by competing-risk analysis reﬂects the probability of a prostate cancer diagnosis in a real-world scenario,
whereby death from other causes is taken into account.
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in why men with hypertension have a lower risk of prostate
cancer. Selection bias may explain these observations, but it is
equally possible that men with hypertension have a different
metabolic proﬁle, which makes them less likely to develop
prostate cancer. Thus, to the best of our knowledge, no
statistical method can answer questions on aetiology like
these in a scenario where competing risks are an issue.
To summarise, with this example we would like to encourage
clinical researchers to distinguish between the risk calculated
using conventional survival and competing-risk methods. In
many study scenarios these two will result in similar ﬁndings,
but in studies of populations with high mortality (e.g. elderly)
or when the main exposure of interest is associated with a
competing event (e.g. smoking or obesity and risk of death),
the risk calculated from competing-risk analysis is required to
provide a full understanding of the association studied.
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